BT-001
BT-001 is a multifunctional oncolytic virus
encoding for an anti-CTLA4 antibody and GM-CSF
BT-001 is the first oncolytic virus from Invir.IO® and is optimized to act as a Trojan horse.
Two specific “weapons” have been integrated into the Vaccinia viral DNA: an anti-CTLA4 antibody, which was developed by BioInvent, and the cytokine GM-CSF, which triggers the body’s immune response.
Discover how BT-001 works
Collaboration agreement
BioInvent and Transgene are together creating a novel armed oncolytic virus that will be able to infect and selectively replicate within the tumor, inducing cancer cell destruction, and to elicit a strong immune response that is further enhanced by the local expression of the immune checkpoint inhibitor and the cytokine. This novel oncolytic virus is expected to deliver better treatment outcomes with an improved safety profile as the patient is not exposed to the the anti-CTLA4 antibody at a systemic level.
Transgene and BioInvent have entered into a clinical trial collaboration and supply agreement with MSD, a tradename of Merck & Co., Inc., Rahway, NJ., USA, to evaluate the combination of the oncolytic virus BT-001 in combination with MSD’s anti-PD-1 checkpoint therapy KEYTRUDA® (pembrolizumab) in a Phase I/IIa clinical trial for the treatment of patients with solid tumors.”
Clinical trials
| Indication | Phase | |
|---|---|---|
| Solid tumors | Phase I/IIa | More information |
Key figures
SITC 2021, Semmrich et al, Poster, see poster
SITC 2020, Semmrich et Al, Poster, see poster
Semmrich et al. Journal of ImmunoTherapy of Cancer, 2022. Download
- September 14, 2024 - Transgene and BioInvent’s Oncolytic Virus BT-001 Shows Promising Antitumor Activity in Ongoing Phase I/IIa Trial in Solid Tumors that Failed Previous Treatment
- July 22, 2024 - Transgene and BioInvent to Present Poster on Oncolytic Virus, BT-001, at ESMO 2024
- October 10, 2023 - Transgene and BioInvent – First patient treated in Part B of Phase I trial assessing the novel oncolytic virus BT-001 in combination with KEYTRUDA®(pembrolizumab)
- Initial clinical results of BT-001, an oncolytic virus expressing an anti-CTLA4 mAb, administered as single agent and in combination with pembrolizumab in patients with advanced solid tumors
S. Champiat, et al.
ESMO 2024 Abstract available on the ESMO website – Download the abstract and the poster - Comprehensive preclinical studies of BT-001: an oncolytic vaccinia virus armed with Treg-depleting @CTLA4 and GM-CSF
- Vectorized Treg-depleting αCTLA-4 elicits antigen cross-presentation and CD8+ T cell immunity to reject “cold” tumors
Semmrich M, Marchand J, Fend L, et al
Journal for ImmunoTherapy of Cancer
Download the publication here
Publication